Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Jumped Today

By Keith Speights - Jun 26, 2020 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst upped his price target for the drugmaker.

What happened

Shares of BioCryst Pharmaceuticals (BCRX 1.14%) up 10.8% to around $4.76 Friday as of 3:30 p.m. EDT. The big gain came after JMP Securities analyst Jonathan Wolleben bumped his price target for the stock up to $11 from $10.

So what

It's typically best to take analysts' price targets for stocks with a grain of salt. However, understanding the rationales behind their perspectives can be helpful in evaluating the prospects for a company.

Thumb up with a hand holding $100 bills fanned out

Image source: Getty Images.

In this case, Wolleben is expecting that BioCryst's hereditary angioedema drug berotralstat will win a thumbs-up from the FDA. The agency is scheduled to announce its decision on the drug by Dec. 3. Wolleben estimates that there's an 80% chance that berotralstat will win FDA approval based on its positive clinical results.

He is also upbeat about BioCryst's oral factor D inhibitor, BCX9930. The drugmaker initiated a proof-of-concept clinical trial in March evaluating the drug in treating paroxysmal nocturnal hemoglobinuria.

Is Wolleben's optimism justified? Probably so. Around 85% of drugs that successfully complete phase 3 testing go on to win FDA approval, based on historical data analyzed by biopharmaceutical industry trade organization BIO. If approved, berotralstat could generate peak annual sales of more than $500 million, which would likely make the JMP Securities price target of $11 per share attainable. 

Now what

The key thing to watch now with this biotech stock will be the FDA's decision on berotralstat. BioCryst also awaits European approval of the drug, which is expected in early 2021.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
BCRX
$14.21 (1.14%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.